Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)

Passage Bio and PepGen are small-cap biotech peers with similar insider and institutional ownership (Passage: 53.5% institutional, 5.0% insiders; PepGen: 58.0% institutional, 5.2% insiders). Both companies are unprofitable—Passage reported net loss of $64.77M (EPS -$14.40, P/E -0.64) while PepGen reported a larger net loss of $89.98M (EPS -$2.82, P/E -1.93)—and have negative ROE/ROA (Passage ROE -102.09% / ROA -52.97%; PepGen ROE -84.15% / ROA -65.59%). Analyst coverage from MarketBeat shows Passage with 1 sell and 3 buy ratings (rating score 2.50) and PepGen with 2 sell and 4 buy ratings (rating score 2.33); PepGen is noted as trading at a lower P/E and 'beats' Passage on 6 of 11 compared factors, while both stocks exhibit high volatility (betas ~1.86–1.91).

Analysis

Market structure: PepGen (PEPG) is the nearer-term “winners” candidate because it trades cheaper on per‑share loss and has a more focused lead program (DMD) that can re-rate on Phase‑2 progress; Passage Bio (PASG) is the loser in the short term due to wider pipeline burn and more negative sentiment. Institutional ownership (~55–58%) and high betas (~1.9) mean both move with biotech flows — a risk‑off in small‑cap biotech will disproportionately hurt PASG given its deeper cash burn and broader program set. Cross‑asset: expect higher implied volatility in options for both tickers, modest widening in high‑yield biotechs' credit spreads if markets reprice clinical risk, and no meaningful FX/commodity impact outside risk‑off flows increasing USD demand.

Risk assessment: Tail risks are binary clinical failures, FDA non‑approvable letters, or a mid‑cycle financing that dilutes >15–25% — either could drop equity >40% quickly; conversely, a positive readout could produce 2–4x moves. Time horizons: immediate (days) = elevated IV and news sensitivity; short (1–6 months) = catalyst windows/financing; long (12–36 months) = commercial proof and M&A potential. Hidden dependencies include reliance on CDMO partners (Catalent for PASG) and potential milestone‑linked payments; second‑order effect is that successful trial readouts increase takeover probability and dry up arbitrage opportunities.

Trade implications: Primary actionable is a dollar‑neutral pair: go long PEPG and short PASG to isolate idiosyncratic clinical risk while capturing relative re‑rating (suggest 1:1 dollar exposure, 1–3% NAV each leg). Options: buy 6–9 month PEPG calls ~25–40% OTM (or 1.5–2x delta if liquidity limited) and buy protective 6–9 month PASG puts to hedge a biotech drawdown. Rotate out of undifferentiated small‑cap biotechs into names with clear 6–12 month binary catalysts; trim overall small‑cap biotech exposure to <5% NAV until next quarter’s readouts.

Contrarian angles: The market may be over‑penalizing PASG for breadth — a single positive data point on a lead CNS program could trigger outsized recovery and M&A interest, so deep OTM PASG calls or a small options‑funded long are asymmetric. Conversely, consensus may underprice competitive and pricing risk in DMD; don’t overleverage PEPG without vetting exon‑skipping competitive timelines. Historical parallels: gene/oligo winners often show 100–300% moves post‑readout but are followed by mean reversion; plan exits at +50–100% and stop losses at −30% to capture this pattern.

Key Decisions for Investors

• Establish a dollar‑neutral pair trade: go long PEPG equal to 1.5% of fund NAV and short PASG equal to 1.5% NAV (dollar‑neutralize) to capture relative value ahead of upcoming clinical/financing windows over 3–9 months; trim if PEPG rises +50% or PASG falls −30%.
• Buy 6–9 month PEPG calls sized at 0.5–1.0% NAV (prefer 25–40% OTM or ~1.5–2.0 delta if liquidity allows) and simultaneously buy 6–9 month PASG puts (size 0.5% NAV) to create an asymmetric risk profile if volatility spikes; exit or roll at 75% IV decay or 50% gain.
• If PASG equity declines >20% on no new adverse clinical data, allocate a tactical speculative sleeve (0.5% NAV) to deep OTM calls (12+ month LEAPS if available) as a takeover/multi‑program recovery asymmetric play; cap total exposure to 1% NAV.
• Reduce broad small‑cap biotech exposure by 25% (reallocate to larger, catalyst‑rich names or cash) until the next 90‑day window of clinical readouts and financing timelines; favor names with >=12 months cash runway or firm partner funding.